Professional Documents
Culture Documents
Essential Role of Contract Research Organization (CROs) in Pakistan
Essential Role of Contract Research Organization (CROs) in Pakistan
Essential Role of Contract Research Organization (CROs) in Pakistan
A CRO can be described as an organization/person that is contracted by a sponsor to manage various steps in the drug
development process, including conduct of preclinical studies, clinical study design and execution, data management,
analysis, medical writing, and regulatory submission.
Services provided by a CRO: The types of services may be one or many or full-service provider CROs may offer an
exhaustive list of core and ancillary R&D services. Listed below are services that from a practical aspect are more
applicable to Pakistan in the near term:
• Drug development (including nutraceuticals and herbal medicines)
• Preclinical testing
• Clinical trial/study management
• Biostatistical Analysis
• Data management
• Laboratory services
• Bioequivalence studies
• Post-marketing surveillance / Observational studies
• Regulatory affairs consultation
• Medical writing (i.e. protocol, clinical study reports, publication)
Types of Relationships
Why Outsource?: There are several reasons and mostly it is due to prevalent global economic recession and down-
sizing all revolving around seeking avenues of revenue generation and optimization. Other reasons are as follows:
• Lack of internal capacity / expertise
www.pulsepakistan.com/index.php/main-news-feb-1-14/630-essential-role-of-contract-research-organization-cros-in-pakistan?tmpl=component&print=1&layou… 1/3
04/02/2023, 08:21 Essential Role of Contract Research Organization (CROs) in Pakistan
• Strategy / policy to outsource certain programs
• Focus on operations
• Cost savings
• Allow sponsor to focus on its core competencies
The CRO Advantage: CROs bring with them a wealth of experience of working with many different products, regulatory
regions, organizations and quality systems, which allows them to quickly integrate into the operations of the sponsor
organization. It allows the sponsor to quickly take advantage of different markets and opportunities due the immediate
availability of expert personnel, knowledge and equipment. This avoids the need for the sponsor to invest in capital
equipment or hire specialist staff. The costs of projects are agreed in advance, therefore the cost of development is
defined at the outset and the cost of a project can be directly controlled. These relationships also allow a company to
expand into, or take advantage of, technologies that are not its traditional expertise.
Disadvantages: CROs being businesses themselves may penalize sponsors in the event of unforeseen circumstances
such as early termination of projects, delays or additional requirements (translating into additional costs). However, if a
sponsor can manage a project in a manner that results in minimization of long term R&D expenses while containing
short-term costs, they will obtain a net advantage in hiring on services of a CRO.
CROs Worldwide Presence: The CRO sector is highly fragmented with over 1,100 CROs worldwide, although more
than two thirds of all CROs are based in the US. CROs come in many shapes and sizes: some are specialized in certain
services in certain areas (the small specialty CROs), and some offer the whole spectrum of services in a drug
development process around the world. This latter group comprises the global full service CROs, which have a presence
in all emerging markets. Of the major global CROs, Quintiles is the market leader, with 14% of the global market share;
followed by Covance and Pharmaceutical Product Development (PPD), which hold 10% each of the market share (see
Table below). The five largest CROs hold 45% of the total market between them.
Nearly 70% of the total research and development (R&D) costs are spent on clinical trials. Clinical trials are a key factor
in the rising R&D costs because today’s drug trials are larger and more complicated on average and require more
participants than ever before. In addition, recruiting participants is becoming more difficult in western countries. In 2008,
US Pharma companies spent $32.2 billion on trials. Pharmaceutical companies are under pressure to bring more new
drugs to the market while at the same time they have to cut their R&D budgets. As a result, companies are increasingly
outsourcing their R&D to Contract Research Organizations (CROs), which offer services that can increase R&D
effectiveness and at lower costs. Currently, about half of the clinical trial activities are outsourced to CROs. The CRO
market is estimated to account for $24 billion in 2010.Over 50% growth to 2015 seen in global clinical trials market.
Conclusion
Taking cues from the western model, Pakistani businesses such as pharmaceutical companies, private and public
institutions and hospitals can benefit significantly from this CRO-Sponsor partnership paradigm which translates to value
addition, efficiency and cost savings while assuring quality, data integrity and patient safety.
References
1. http://www.cipher-sys.com/Global%20Contract%20Research%20Organizations.pdf, 2008.
2. http://www.evotec.com/uploads/cms_article/192/Evotec_Initial_coverage_2010-07-30.pdf
3. Tufts Center for the Study of Drug Development. “Tufts CSDD Outlook
www.pulsepakistan.com/index.php/main-news-feb-1-14/630-essential-role-of-contract-research-organization-cros-in-pakistan?tmpl=component&print=1&layou… 2/3
04/02/2023, 08:21 Essential Role of Contract Research Organization (CROs) in Pakistan
2010”.http://csdd.tufts.edu/_documents/www/Outlook2010.pdf (accessed 30 December 2010).
4. Visiongain report, Pharma Clinical Trial Services: World Market 2011-2021
www.pulsepakistan.com/index.php/main-news-feb-1-14/630-essential-role-of-contract-research-organization-cros-in-pakistan?tmpl=component&print=1&layou… 3/3